Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Kira Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): P014

            Therapeutic Area: Immunology Product Name: P014

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Quan Capital

            Deal Size: $46.0 million Upfront Cash: Undisclosed

            Deal Type: Financing November 12, 2020

            Details:

            Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.